Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

In the 24-week, placebo-controlled period of the phase 3 UP-AA program, both 15 mg and 30 mg doses of Upadacitinib (UPA) showed superior efficacy in treating severe alopecia areata (AA) in adults and adolescents compared to placebo. The safety profile of UPA was consistent with its use in other approved indications. Further evaluation of UPA's efficacy, safety, and tolerability in this patient population is ongoing in the UP-AA phase 3 clinical program.